Featured Research

from universities, journals, and other organizations

Proteins that deliver leucine to prostate cancer cells are therapeutic targets

Date:
September 19, 2013
Source:
Journal of the National Cancer Institute
Summary:
Like normal cells, cancer cells require amino acids for growth, maintenance, and cell signaling, and L-type amino acid transporters (LATs) are the delivery vehicles that supply them. Metastatic, castration-resistant prostate cancer cells are highly dependent on LATs to deliver the amino acid leucine that the cells need for growth and proliferation.

Like normal cells, cancer cells require amino acids for growth, maintenance, and cell signaling, and L-type amino acid transporters (LATs) are the delivery vehicles that supply them. Metastatic, castration-resistant prostate cancer (CRPC) cells are highly dependent on LATs to deliver the amino acid leucine that the cells need for growth and proliferation, according to a study published September 19 in the Journal of the National Cancer Institute.

Related Articles


To investigate the function of LATs in prostate cancer, Qian Wang, Ph.D., of the Origins of Cancer Laboratory, Centenary Institute, Sydney, Australia, and colleagues studied LAT3 expression in tissue samples from prostate cancer patients, analyzed the function of LATs in cancer cells in vitro, used microarray data to determine which genes and pathways are associated with LAT function, and assessed the role of LAT1 and LAT3 in tumor formation, growth, and metastasis in mice.

The researchers found that LAT3 was expressed at all stages of prostate cancer and that inhibition of LAT proteins inhibits nutrient signaling pathways and over 100 metastasis-related genes, including E2F transcription factors, resulting in cell cycle inhibition. In mice injected with prostate cancer cells, tumor formation, metastasis, and cell cycle progression were all inhibited when the LAT1 or LAT3 gene was knocked out.

The authors conclude that "Targeting LAT transporters, thereby inhibiting leucine uptake, may offer a new therapeutic opportunity for metastatic CRPC, affecting tumor growth and metastasis through inhibition of M-phase cell cycle and mTORC1 signaling pathways." Wang et al. note, however, that further investigation into the long-term effects of leucine deprivation is needed, as well as the effects on other cell types and resistance mechanisms.

In an accompanying editorial, Andrew R. Tee, Ph.D., of the Institute of Cancer and Genetics at Cardiff University, Wales, writes, "Such new evidence explains why malignant prostate cancer has an appetite for amino acids, where these amino acids are quickly utilized to drive their growth and proliferation." Tee adds that this discovery will have huge implications for both prostate cancer studies and therapies.


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Wang et al. Proteins that Deliver Leucine to Prostate Cancer Cells Are Therapeutic Targets. Journal of the National Cancer Institute, September 2013 DOI: 10.1093/jnci/djt288

Cite This Page:

Journal of the National Cancer Institute. "Proteins that deliver leucine to prostate cancer cells are therapeutic targets." ScienceDaily. ScienceDaily, 19 September 2013. <www.sciencedaily.com/releases/2013/09/130919163148.htm>.
Journal of the National Cancer Institute. (2013, September 19). Proteins that deliver leucine to prostate cancer cells are therapeutic targets. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2013/09/130919163148.htm
Journal of the National Cancer Institute. "Proteins that deliver leucine to prostate cancer cells are therapeutic targets." ScienceDaily. www.sciencedaily.com/releases/2013/09/130919163148.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) — Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) — Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) — AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Adults Only Get The Flu Twice A Decade, Researchers Say

Adults Only Get The Flu Twice A Decade, Researchers Say

Newsy (Mar. 4, 2015) — Researchers found adults only get the flu about once every five years. Scientists analyzed how a person&apos;s immunity builds up over time as well. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins